Kähkönen TE, Suominen MI, Halleen JM, Bernoulli J 2021 Preclinical Bone Metastasis Models Chapter of a book ‘Animal Models for Development of Cancer Immunotherapy’. In press (Invited book chapter, estimated publication March 2021).

Kähkönen TE, Halleen JM, Bernoulli J 2019 Potential of Targeting Bone Metastases with Immunotherapies. Nov Appro In Can Study 3(3):269-270 (invited review article).

Kähkönen TE, Suominen MI, Mäki-Jouppila JHE, Halleen JM, Tanaka A, Seiler M, Bernoulli J 2019 Human Immune System Increases Breast Cancer-Induced Osteoblastic Bone Growth in a Humanized Mouse Model without Affecting Normal Bone. J Immunol Res 2019/4260987.

Kähkönen TE, Bernoulli J, Halleen JM, Suominen MI 2019 Novel and Conventional Preclinical Models to Investigate Bone Metastasis. Curr Mol Biol Rep 5(1):48-54 (invited review article).

Kähkönen TE, Tuomela JM, Grönroos TJ, Halleen JM, Ivaska KK, Härkönen PL 2018 Dovitinib dilactic acid reduces tumor growth and tumor-induced bone changes in an experimental breast cancer bone growth model. J Bone Oncol 16:100232.

Juzeniene A, Bernoulli J, Suominen M, Halleen J, Larsen RH 2018 Antitumor Activity of Novel Bone-seeking, α-emitting 224Ra-solution in a Breast Cancer Skeletal Metastases Model. Anticancer Res 38(4):1947-1955.

Suominen MI, Fagerlund KM, Rissanen JP, Konkol Y, Morko J, Peng Z, Alhoniemi E, Laine S, Corey E, Mumberg D, Ziegelbauer K, Käkönen S, Halleen JM, Vessella  R, Scholz A 2017 Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models. Clin Cancer Res 23(15):4335-46.

Valta M, Fagerlund K, Suominen M, Halleen J, Tuomela J 2015 Importance of microenvironment in preclinical models of breast and prostate cancer. World J Pharmacol 4:47-57 (invited review article).

Tang C, Liu Y, Qin H, Li X, Guo W, Li J, Wang W, Qu L, Hu H, Xu C, Zheng L, Huang Y, Liu B, Gao H, Halleen JM, Liu X 2013 Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients. Clin Chim Acta 426:102-107.

Suominen MI, Rissanen JP, Käkönen R, Fagerlund KM, Alhoniemi E, Mumberg D, Ziegelbauer K, Halleen JM, Käkönen SM, Scholz A 2013 Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis. J Natl Cancer Inst 105:908-916.

Pollari S, Käkönen RS, Mohammad KS, Rissanen JP, Halleen JM, Wärri A, Nissinen L, Pihlavisto M, Marjamäki A, Perälä M, Guise TA, Kallioniemi O, Käkönen SM 2012 Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis. Mol Cancer Res 10:597-604.

Korpela J, Tiitinen SL, Hiekkanen H, Halleen JM, Selander KS, Väänänen HK, Suominen P, Helenius H, Salminen E 2006 Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer. Anticancer Res 26:3127-3132.

Salminen E, Ala-Houhala M, Korpela J, Varpula M, Tiitinen SL, Halleen JM, Väänänen HK 2005 Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer. Acta Oncol 44:742-747.

OncoBone

AT YOUR SERVICE

If you are interested to learn more,
see our services or contact us directly.

    Scientist.com logo Science Exchange logo

    Copyright © 2020 OncoBone Ltd